

# Alembic gets FDA nod Efinaconazole topical solution

The approved generic is therapeutically equivalent to Jublia Topical Solution, of Bausch Health and has an estimated market size of \$500 million in the US.



Mumbai: Ahmedabad-based Alembic Pharmaceuticals has obtained final approval for its efinaconazole topical solution in the US.

Efinaconazole is indicated for the topical treatment of onychomycosis of the

toenail(s) due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

The approved generic is therapeutically equivalent to Jublia Topical Solution, of Bausch Health and has an estimated market size of \$500 million in the US.

Alembic has secured marketing approval with a paragraph IV certification, enabling the company to potentially secure 180 days of market exclusivity for its generic formulation.

## News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/alembic-gets-fda-nod-efinaconazole-topical-solution/128753024>